Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage

Phase 2

Completed

• Conditions: Atopic Dermatitis; Atopic Eczema
• Interventions: Drug: Omalizumab (Xolair®)

• Registration Number: NCT01179529
• Lead Sponsor: Technical University of Munich

Brief Summary

This study aims at evaluating the therapeutic potential of omalizumab in atopic dermatitis, and to work out biomarkers predictive of treatment response.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-08-02
• Study First Submitted QC: 2010-08-09
• Study First Posted: 2010-08-11
• Status Verified: 2012-01
• Last Update Submitted: 2012-01-09
• Last Update Posted: 2012-01-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Age ≥ 18-70 years of age, body weight ≥ 20 kg and ≤ 150 kg
• Dermatological diagnosis of AD, SCORAD >=20
• A positive RAST (≥CAP1) result for at least one aeroallergen specific IgE and total IgE >=100kU/l at screening (or within the previous 12 months)
• Eligible to receive systemic therapy for AD in accordance to local guidelines
• Signed informed consent from patient

Exclusion Criteria

• Evidence of skin disease other than AD (e.g. psoriasis) at the inclusion time
• Treatment with systemic AD medications or any investigational drug within a 30-day washout period
• Concomitant treatment with substances interfering with the immune system
• Permanent severe diseases, especially those affecting the immune system, except asthma
• Pregnancy or breast feeding
• History of food or drug related severe anaphylactoid or anaphylactic reaction(s)
• History or presence of epilepsy, significant neurological disorders, cerebrovascular attacks or ischemia
• History or presence of myocardial infarction or cardiac arrhythmia which requires drug therapy
• Elevated serum IgE levels for reasons other than allergy and/or urticaria (e.g.: parasite infections, hyperimmunoglobulin E syndrome, Wiskott - Aldrich syndrome or clinical allergic bronchopulmonary aspergillosis)
• Evidence of severe renal dysfunction or significant hepatic disease
• Evidence for active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy
• History of malignancy of any organ system, treated or untreated, whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin
• Clinically significant laboratory abnormalities (not associated with AD) at Visit 1
• Known hypersensitivity to any ingredients, including excipients (sucrose, histidine, polysorbate 20) of the study medication or drugs related to Omalizumab (e.g.: monoclonal antibodies, polyclonal gammaglobulin)
• Patients who are considered potentially unreliable or where it is envisaged the patient may not consistently attend scheduled study visits
• Patients with serious psychiatric and/or psychological disturbances
• Patients with a history of drug or alcohol abuse
• Patients who are unable to complete a patient diary or complete questionnaires on paper
• Patients with any other condition or prior/current treatment, which in the opinion of the investigator renders the patient ineligible for the study schedule

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Omalizumab	Omalizumab (Xolair®)	-

Primary Outcome Measures

Name	Time	Method
To evaluate efficacy of Omalizumab treatment in a sample of adult patients with moderate to severe AD

Trial Locations

Locations (1)

Klinikum rechts der Isar Dermatologie/Biederstein; 🇩🇪 Munic, Bavaria, Germany